High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission

Annals of the Rheumatic Diseases

Volumn 74, Issue 4, 2015, Pages 655-660

  Araujo, Elizabeth G ^a   Finzel, Stephanie ^a   Englbrecht, Matthias ^a   Schreiber, Dominik A ^a   Faustini, Francesca ^a   Hueber, Axel ^a   Nas, Kemal ^a,b   Rech, Juergen ^a   Schett, Georg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b DICLE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; HUMAN; INCIDENCE; LOW DRUG DOSE; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; RECURRENCE RISK; REMISSION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; JOINT; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; JOINTS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84925674808     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204229     Document Type: Article

References (23)

1. Veale DJ. New therapies and new goals for psoriatic arthritis. Arthritis Rheum 2011; 63: 874-6.
2. Kane D, Stafford L, Bresnihan B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience. Rheumatology (Oxford) 2003; 42: 1460-8.
3. Gladman DD, Thavaneswaran A, Chandran V, et al. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis 2011; 70: 2152-4.
4. Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, et al. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003; 62: 68-70.
5. Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: Short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis 2014; 73: 407-13.
6. Baranauskaite A, Raffayova H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: The RESPOND study. Ann Rheum Dis 2012; 71: 541-8.
7. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-94.
8. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012; 51: 1368-77.
9. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005; 64(Suppl 2): Ii74-7.
10. Caperon A, Helliwell PS. Remission in psoriatic arthritis. J Rheumatol Suppl 2012; 89: 19-21.
11. Coates LC, Mumtaz A, Helliwell PS, et al. Development of a disease severity and responder index for psoriatic arthritis (PsA)-report of the OMERACT 10 PsA special interest group. J Rheumatol 2011; 38: 1496-501.
12. Kavanaugh A, Fransen J. Defining remission in psoriatic arthritis. Clin Exp Rheumatol 2006; 24: S-83-7.
13. Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken) 2011; 63(Suppl 11): S64-85.
14. Palominos PE, Gaujoux-Viala C, Fautrel B, et al. Clinical outcomes in psoriatic arthritis: A systematic literature review. Arthritis Care Res (Hoboken) 2012; 64: 397-406.
15. Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010; 69: 1441-7.
16. Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013; 72: 986-91.
17. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: A proposed objective target for treatment. Ann Rheum Dis 2010; 69: 48-53.
18. Saber TP, Ng CT, Renard G, et al. Remission in psoriatic arthritis: Is it possible and how can it be predicted? Arthritis Res Ther 2010; 12: R94.
19. Cantini F, Niccoli L, Cassara E, et al. Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: A long-Term follow-up study. Biologics 2012; 6: 201-6.
20. Olivieri I, D'Angelo S, Padula A, et al. Can we reduce the dosage of biologics in spondyloarthritis? Autoimmun Rev 2013; 12: 691-3.
21. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-Alpha-And RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111: 821-31.
22. Cantini F, Niccoli L, Nannini C, et al. Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs. J Rheumatol Suppl 2009; 83: 78-80.
23. Gladman DD, Hing EN, Schentag CT, et al. Remission in psoriatic arthritis. J Rheumatol 2001; 28: 1045-8.